Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy

CONCLUSIONS: We constructed a TGCP model, which demonstrates satisfactory predictive accuracy. Out of 9 prognostic genes, TAP1 was validated as a synergistic target for Oxaliplatin and PDL1 inhibitors, offering a genetic-level explanation for the synergy observed in GC treatment involving Oxaliplatin in combination with PDL1 inhibitors.PMID:38593510 | DOI:10.1016/j.intimp.2024.111998

Source: International Immunopharmacology - April 9, 2024 Category: Allergy & Immunology Authors: Yupeng Zhao Ziyuan Liu Kaiyuan Deng Huiheng Qu Qing Zhang Peng Zhou Mengqi Yang Xiao Yang Hao Wang Ranran Li Jiazeng Xia Source Type: research